Polymer–Lipid Pharmaceutical Nanocarriers: Innovations by New Formulations and Production Technologies DOI Creative Commons
Sabrina Bochicchio, Gaetano Lamberti, Anna Angela Barba

и другие.

Pharmaceutics, Год журнала: 2021, Номер 13(2), С. 198 - 198

Опубликована: Фев. 2, 2021

Some issues in pharmaceutical therapies such as instability, poor membrane permeability, and bioavailability of drugs can be solved by the design suitable delivery systems based on combination two pillar classes ingredients: polymers lipids. At same time, modern technologies are required to overcome production limitations (low productivity, high energy consumption, expensive setup, long process times) pass at industrial level. In this paper, a summary applications polymeric lipid materials combined nanostructures (hybrid nanocarriers) is reported. Then, recent techniques adopted hybrid nanoparticles discussed, highlighting still present that hold back implementation.

Язык: Английский

Hollow Nanomaterials in Advanced Drug Delivery Systems: From Single‐ to Multiple Shells DOI
Li Zhao, Ke Xu, Linlin Qin

и другие.

Advanced Materials, Год журнала: 2022, Номер 35(12)

Опубликована: Авг. 23, 2022

Hollow-structured nanomaterials (HSNMs) have attracted increased interest in biomedical fields, owing to their excellent potential as drug delivery systems (DDSs) for clinical applications. Among HSNMs, hollow multi-shelled structures (HoMSs) exhibit properties such high loading capacity, sequential release, and multi-functionalized modification represent a new class of nanoplatforms The remarkable HoMS-based DDS can simultaneously satisfy enhance DDSs delivering small molecular drugs (e.g., antibiotics, chemotherapy drugs, imaging agents) macromolecular protein/peptide- nucleic acid-based drugs). First, the latest research advances are summarized highlight inherent advantages targeting, combining continuous therapeutic theranostics optimize benefit. Meanwhile, initial development stage currently offer limited modes. There is growing need analyze deficiency other HSNMs integrate providing solutions safe, stable, cascade meet vast treatment requirements. Therefore, comprehensively reviewed, mainly focusing on characteristics, progress by category, future prospects.

Язык: Английский

Процитировано

67

Challenges in delivering therapeutic peptides and proteins: A silk-based solution DOI
Junqi Wu, Jugal Kishore Sahoo,

Yamin Li

и другие.

Journal of Controlled Release, Год журнала: 2022, Номер 345, С. 176 - 189

Опубликована: Фев. 11, 2022

Язык: Английский

Процитировано

62

Dodging blood brain barrier with “nano” warriors: Novel strategy against ischemic stroke DOI Creative Commons
Suhel Parvez,

Medha Kaushik,

Mubashshir Ali

и другие.

Theranostics, Год журнала: 2021, Номер 12(2), С. 689 - 719

Опубликована: Дек. 15, 2021

Ischemic stroke (IS) is one of the leading causes death and disability resulting in inevitable burden globally. injury initiates cascade pathological events comprising energy dwindling, failure ionic gradients, blood brain barrier (BBB), vasogenic edema, calcium over accumulation, excitotoxicity, increased oxidative stress, mitochondrial dysfunction, inflammation eventually cell death. In spite such complexity disease, only treatment approved by US Food Drug Administration (FDA) tissue plasminogen activator (t-PA). This therapy overcome deficiency along with side effects reperfusion which are responsible for considerable injury. Therefore, there urgent need novel therapeutic perspectives that can protect integrity BBB salvageable tissue. Advancement nanomedicine empowering new approaches potent to improve understanding IS. Herein, we focus nanomaterial mediated drug delivery systems (DDSs) their role bypass cross especially via intranasal delivery. The various nanocarriers used DDSs also discussed. a nut shell, objective provide an overview use diagnosis IS facilitate research from benchtop bedside.

Язык: Английский

Процитировано

61

Next-generation contact lenses: Towards bioresponsive drug delivery and smart technologies in ocular therapeutics DOI
Pinal Chaudhari, Vivek Ghate, Shaila A. Lewis

и другие.

European Journal of Pharmaceutics and Biopharmaceutics, Год журнала: 2021, Номер 161, С. 80 - 99

Опубликована: Фев. 17, 2021

Язык: Английский

Процитировано

57

Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics DOI Creative Commons
Yunhan Zhang,

Zhulin Zou,

Shuang Liu

и другие.

Frontiers in Bioengineering and Biotechnology, Год журнала: 2022, Номер 10

Опубликована: Июль 19, 2022

Nanogels have come out as a great potential drug delivery platform due to its prominently high colloidal stability, loading, core-shell structure, good permeation property and can be responsive environmental stimuli. Such nanoscopic carriers more excellent abilities over conventional nanomaterials for permeating brain parenchyma

Язык: Английский

Процитировано

44

Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols DOI Creative Commons

Wafaa Alabsi,

Basanth Babu Eedara, David Encinas-Basurto

и другие.

Pharmaceutics, Год журнала: 2022, Номер 14(9), С. 1870 - 1870

Опубликована: Сен. 5, 2022

Central nervous system (CNS) disorders, such as psychiatric neurodegeneration, chronic pain, stroke, brain tumor, spinal cord injury, and many other CNS diseases, would hugely benefit from specific potent peptide pharmaceuticals their low inherent toxicity. The delivery of peptides to the is challenging due metabolic stability, which decreases duration action, poor penetration blood-brain barrier (BBB), incompatibility with oral administration, typically resulting in need for parenteral administration. These challenges limit peptides' clinical application explain interest alternative routes particularly nose-to-brain (N-to-B) delivery, allows protein drugs reach noninvasively. N-to-B can be a convenient method rapidly targeting CNS, bypassing BBB, minimizing systemic exposure; olfactory trigeminal nerves provide unique pathway external environment. This review highlights intranasal drugs, focusing on illustrating various applications, nasal devices, scope limitations this approach.

Язык: Английский

Процитировано

43

Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials DOI Open Access
Md. Harun-Or-Rashid,

Most. Nazmin Aktar,

Md. Sabbir Hossain

и другие.

Polymers, Год журнала: 2023, Номер 15(23), С. 4563 - 4563

Опубликована: Ноя. 28, 2023

Polymeric drug delivery technology, which allows for medicinal ingredients to enter a cell more easily, has advanced considerably in recent decades. Innovative medication strategies use biodegradable and bio-reducible polymers, progress the field been accelerated by future possible research applications. Natural polymers utilized polymeric systems include arginine, chitosan, dextrin, polysaccharides, poly(glycolic acid), poly(lactic hyaluronic acid. Additionally, poly(2-hydroxyethyl methacrylate), poly(N-isopropyl acrylamide), poly(ethylenimine), dendritic bioabsorbable as well biomimetic bio-related drug-free macromolecular therapies have employed delivery. Different synthetic natural biomaterials are clinical phase mitigate different diseases. Drug methods using becoming increasingly common pharmaceutical industry, with biocompatible copolymers dendrimers having helped cure cancer systems. This review discusses all above components how, combining biological approaches, micro- nano-drug can result revolutionary gene devices.

Язык: Английский

Процитировано

28

Ocular Delivery of Therapeutic Proteins: A Review DOI Creative Commons
Divyesh H. Shastri, Ana Catarina Silva, Hugo Almeida

и другие.

Pharmaceutics, Год журнала: 2023, Номер 15(1), С. 205 - 205

Опубликована: Янв. 6, 2023

Therapeutic proteins, including monoclonal antibodies, single chain variable fragment (ScFv), crystallizable (Fc), and antigen binding (Fab), have accounted for one-third of all drugs on the world market. In particular, these medicines been widely used in ocular therapies treatment various diseases, such as age-related macular degeneration, corneal neovascularization, diabetic retinopathy, retinal vein occlusion. However, formulation biomacromolecules is challenging due to their high molecular weight, complex structure, instability, short half-life, enzymatic degradation, immunogenicity, which leads failure therapies. Various efforts made overcome barriers, providing effective delivery therapeutic altering protein structure or it new systems. These strategies are not only cost-effective beneficial patients but also shown allow fewer drug side effects. this review, we discuss several factors that affect design formulations proteins tissues, use injectable micro/nanocarriers, hydrogels, implants, iontophoresis, cell-based therapy, combination techniques. addition, other approaches briefly discussed, related structural modification improving bioavailability posterior segments eye without affecting stability. Future research should be conducted toward development more effective, stable, noninvasive, proteins. insights into preclinical clinical translation needed.

Язык: Английский

Процитировано

24

Current trends in inhaled pharmaceuticals: challenges and opportunities in respiratory infections treatment DOI

Kiramat Ali Shah,

Anam Razzaq,

Amos Dormocara

и другие.

Journal of Pharmaceutical Investigation, Год журнала: 2025, Номер unknown

Опубликована: Янв. 29, 2025

Язык: Английский

Процитировано

1

In vitro antioxidant activity of Ficus carica L. latex from 18 different cultivars DOI Creative Commons
M. Shahinuzzaman, Zahira Yaakob, Farah Hannan Anuar

и другие.

Scientific Reports, Год журнала: 2020, Номер 10(1)

Опубликована: Июль 2, 2020

Abstract As synthetic antioxidants that are widely used in foods known to cause detrimental health effects, studies on natural additives as potential becoming increasingly important. In this work, the total phenolic content (TPC) and antioxidant activity of Ficus carica Linn latex from 18 cultivars were investigated. The TPC was calculated using Folin–Ciocalteu assay. 1,1-Diphenyl-2-picrylhydrazyl (DPPH), 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) ferric ion reducing power (FRAP) for assessment. bioactive compounds F. extracted via maceration ultrasound-assisted extraction (UAE) with 75% ethanol solvent. Under same conditions, cultivar ‘White Genoa’ showed highest 65.91% ± 1.73% 61.07% 1.65% DPPH, 98.96% 1.06% 83.04% 2.16% ABTS, 27.08 0.34 24.94 0.84 mg TE/g FRAP assay UAE, respectively. 315.26 6.14 298.52 9.20 µg GAE/mL two methods, overall results work is a source antioxidants. This finding useful further advancements fields food supplements, drug synthesis future.

Язык: Английский

Процитировано

69